Home » Regions » Global News » Bracket acquires mProve Health

Bracket acquires mProve Health

Tuesday, October 24, 2017

Bracket, a clinical trial technology and specialty services provider, announced the strategic acquisition of mProve Health, a provider of mobile technologies for life science companies. The acquisition centers on both companies’ support of tech-enabled clinical trials that improve patient engagement through the use of “Bring Your Own Device” mobile tools in clinical trials.

Early-to-market with Electronic Clinical Outcomes Assessments (eCOA) and the first Randomization and Trial Supply Management (RTSM) mobile application, Bracket is at the forefront of digitization in clinical trials. Bracket helps biopharmaceutical sponsors and CROs increase the power of their data and identified a need to bring greater accuracy through technology. Included in mProve’s suite of regulatory compliant mHealth solutions is mPulse, an Electronic Patient-Reported Outcomes (ePRO) platform for enabling data collection via standalone native mobile apps or SMS text. Other apps will enable communication with doctors and provide reminders and education.

In a recent report by KNect365, 94% of clinical trials professionals surveyed are looking to increase the utilization of mHealth, surpassing big data (86%) and cloud technology for EMRs (84%). These findings, among others, indicate mHealth technology as one of the most powerful opportunities in clinical trials. While mainstream eCOA providers are challenged to retrofit their systems to support emerging mHealth technologies and the BYOD movement, Bracket is now positioned for success with native mHealth capability.

“We are excited to announce the acquisition of mProve as we take a major step forward in our support of tech-enabled clinical trials,” said Jeff Kinell, CEO of Bracket. “As an early adopter of mHealth and BYOD, we recognize how these movements empower patients to become partners in their trials, and subsequently, deliver more accurate PRO and increase the likelihood of a successful trial.”

“This acquisition is an opportunity to bring the shared visions of mProve and Bracket into focus,” said Jeff Lee, CEO of mProve. “Both organizations center on improving patient engagement and driving adoption of the mHealth to do so. Together, we are well situated for a future of tech-enabled clinical trials.”

David Golde, Director at Genstar Capital, commented, “We are excited to be supporting Bracket’s first acquisition under Genstar ownership. Combined, Bracket and mProve’s solutions will deliver increased value to clinical trials through the greater use of technology. We look forward to working with Bracket management to continue pursuing strategic acquisitions that allow Bracket to better serve its customers.”

Looking for more news, check out the new FREE CenterWatch Weekly!

The new FREE CenterWatch Weekly is your source of critical news, emerging trends, and business issues around everything in the rapidly changing clinical research marketplace. Check out our new CWWeekly page! Sign up today for your free email newsletter, update your bookmarks and check us out regularly! We look forward to bringing you the best news and information about clinical research in 2018!